Evidence map›Paper›PMID 32803290›Full record

Trial reportEuropean journal of clinical pharmacology2021

Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients.

Rui Dai, Jingjie Li, Jingjing Wu, Qian Fu, Jiajia Yan, Guoping Zhong, Changxi Wang, Xiao Chen, Pan Chen

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Rui Dai *Department of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, Guangzhou, People's Republic of China.
Jingjie Li *Center of Reproductive Medicine, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Jingjing WuDepartment of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, Guangzhou, People's Republic of China.
Qian FuOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Jiajia YanDepartment of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, Guangzhou, People's Republic of China.
Guoping ZhongOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Changxi WangInstitute of Clinical Pharmacology, Sun Yat-sen University, Guangzhou, China.
Xiao ChenDepartment of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, Guangzhou, People's Republic of China. Frankwychen@hotmail.com.ORCID http://orcid.org/0000-0002-9324-5490
Pan ChenDepartment of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, Guangzhou, People's Republic of China. Chenp73@mail.sysu.edu.cn.ORCID https://orcid.org/0000-0003-0271-2725
Sun Yat-sen University · CN

Funding

Guangdong Basic and Applied Basic Research Foundation 2020A1515010138National Key R&D Program of China 2017YFC0909900Young Teacher Foundation of Sun Yat-sen University 19ykpy04Young Teacher Foundation of Sun Yat-sen University 19ykpy79
6 · The paper itself

Abstract

aimMizoribine (MZR) is an immunosuppressant for the prevention of allograft rejection in Asian countries, but the great variability in pharmacokinetics (PK) limits its clinical use. This study was to explore genetic and clinical factors that affect the MZR PK process.

methodsBlood samples and clinical data were collected from 60 Chinese renal transplant recipients. MZR plasma concentration was measured at pre-dose (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, and 12 h post-dose by high performance liquid chromatography with an ultraviolet detector. PK parameters were calculated by non-compartmental analysis. High-throughput sequenced single nucleotide polymorphism was applied screening possible genetic factors.

resultsExtensive inter-individual MZR PK differences were reflected in the process of elimination (k

conclusionCREB1 and SLC28A3 genotypes, as well as SCr, are identified as determinants in predicting inter-individual MZR PK differences in renal transplant recipients.

Indexed as

Kidney TransplantationAdultAgedCyclic AMP Response Element-Binding ProteinCyclosporineFemaleGenotypeGlucocorticoidsHumansImmunosuppressive AgentsMaleMembrane Transport ProteinsMiddle AgedPolymorphism, Single NucleotideRibonucleosidesTacrolimuscif nucleoside transporterCREB1 protein, humanCyclic AMP Response Element-Binding ProteinCyclosporineGlucocorticoidsImmunosuppressive AgentsMembrane Transport ProteinsmizoribineRibonucleosidesTacrolimusGene polymorphismMizoribinePharmacokineticsRenal transplantation

Identifiers

PMID32803290
OpenAlexW3049451085

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.